Ascendis axes IL-2 program in retreat from oncology expansion
Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an asset it once tipped for accelerated ap...
Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an asset it once tipped for accelerated approval.